boothcheck doesn't label RPRX overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, RPRX is priced for growth of +3.4%, and an operating margin near 43.9% versus the 72.7% it earns today. Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium). The more the price assumes beyond what Royalty Pharma plc has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.
Derived from Royalty Pharma plc's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 28, 2026.
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.